Medication info

Pfizer Leucovorin Injection (Calcium Levofolinate)

Prescription medication
Ingredient · strength
Calcium Folinate›10.8mg / 1mL
Manufacturer / importer
Pfizer Pharmaceuticals Korea Limited
Appearance
A transparent yellow injection solution filled in a colorless transparent vial
Packaging
50mg/5mL x 1 vial, 100mg/10mL x 1 vial, 300mg/30mL x 1 vial
Approval status
Active

MFDS item code 199907236 · Notified 1999.11.15 · Insurance code 648903001,648903002,648903003

Summary

Main use
Relief of antifolate toxicity, combination therapy with 5-FU for advanced colorectal cancer
Who uses it
Adults
Adult dosage
(Injection) 1. Conventional methotrexate therapy: If adverse reactions occur at the usual dose of methotrexate (a folic acid antagonist), administer 6-12mg of folinate intramuscularly every 6 hours, 4 times daily. In the event of methotrexate overdose, administer an amount equal to the methotrexate dose given. 2. Methotrexate-folinate rescue therapy: Starting 3 hours after completion of methotrexate administration, administer 15mg of folinate intravenously every 3 hours for 9 doses, followed by intravenous or intramuscular administration every 6 hours for 8 doses. If severe adverse reactions thought to be due to methotrexate occur, increase the dose and extend the duration of treatment. 3. Concomitant use with 5-Fluorouracil (5-FU) for advanced colorectal cancer: Select one of the following two regimens. 1) Administer calcium folinate 200mg/㎡ slowly intravenously over at least 3 minutes, followed by intravenous administration of 5-FU 370mg/㎡. 2) Administer calcium folinate 20mg/㎡ intravenously, followed by intravenous administration of 5-FU 425mg/㎡. Do not administer these drugs simultaneously, as a precipitate may form between 5-FU and folinate. Continue the above treatment for 5 days and repeat it at 4-week intervals. (Tablets) In the event of an overdose of a folic acid antagonist (e.g., methotrexate), administer 10mg of folinate per m2 of body surface area orally every 6 hours as soon as possible (within 1 hour after the overdose) until the serum methotrexate concentration is 10-8M/L or lower. If gastrointestinal toxicity, nausea, or vomiting occurs, administer folinate parenterally. Analyze serum every 24 hours to determine creatinine and methotrexate concentrations. If the serum creatinine concentration 24 hours later is 50% higher than before methotrexate administration, or if the serum methotrexate concentration 24 hours later is 5X10-6M/L or higher, administer a high dose of calcium folinate. Since oral doses of 25mg or more are not recommended, administer parenterally. Provide fluids to maintain urinary output of 1800-2000mL/㎡ per day, and alkalinize the urine with sodium bicarbonate (maintain urine pH at 7.0 or higher) to increase the solubility of methotrexate and its metabolites until the methotrexate concentration is 5×10-8M/L (0.05μM/L).

Ingredients

Importer
Pfizer Pharmaceuticals Korea Limited

Efficacy & effects

Relief of antifolate toxicity, combination therapy with 5-FU for advanced colorectal cancer

  • Toxicity of folate metabolism antagonists
View approved original text

This drug helps reduce toxicity caused by folate metabolism antagonists and is used to enhance treatment effect when used with 5-Fluorouracil (5-FU) in patients with metastatic colorectal cancer.

Dosage and Administration

Adult dosage

(Injection) 1. Conventional methotrexate therapy: If adverse reactions occur at the usual dose of methotrexate (a folic acid antagonist), administer 6-12mg of folinate intramuscularly every 6 hours, 4 times daily. In the event of methotrexate overdose, administer an amount equal to the methotrexate dose given. 2. Methotrexate-folinate rescue therapy: Starting 3 hours after completion of methotrexate administration, administer 15mg of folinate intravenously every 3 hours for 9 doses, followed by intravenous or intramuscular administration every 6 hours for 8 doses. If severe adverse reactions thought to be due to methotrexate occur, increase the dose and extend the duration of treatment. 3. Concomitant use with 5-Fluorouracil (5-FU) for advanced colorectal cancer: Select one of the following two regimens. 1) Administer calcium folinate 200mg/㎡ slowly intravenously over at least 3 minutes, followed by intravenous administration of 5-FU 370mg/㎡. 2) Administer calcium folinate 20mg/㎡ intravenously, followed by intravenous administration of 5-FU 425mg/㎡. Do not administer these drugs simultaneously, as a precipitate may form between 5-FU and folinate. Continue the above treatment for 5 days and repeat it at 4-week intervals. (Tablets) In the event of an overdose of a folic acid antagonist (e.g., methotrexate), administer 10mg of folinate per m2 of body surface area orally every 6 hours as soon as possible (within 1 hour after the overdose) until the serum methotrexate concentration is 10-8M/L or lower. If gastrointestinal toxicity, nausea, or vomiting occurs, administer folinate parenterally. Analyze serum every 24 hours to determine creatinine and methotrexate concentrations. If the serum creatinine concentration 24 hours later is 50% higher than before methotrexate administration, or if the serum methotrexate concentration 24 hours later is 5X10-6M/L or higher, administer a high dose of calcium folinate. Since oral doses of 25mg or more are not recommended, administer parenterally. Provide fluids to maintain urinary output of 1800-2000mL/㎡ per day, and alkalinize the urine with sodium bicarbonate (maintain urine pH at 7.0 or higher) to increase the solubility of methotrexate and its metabolites until the methotrexate concentration is 5×10-8M/L (0.05μM/L).

Precautions

This drug is not suitable for the treatment of pernicious anemia or other megaloblastic anemias due to vitamin B12 deficiency. Even when neurological symptoms persist, caution is required as blood conditions may improve. Glass particles from the injection vial may be introduced, so the vial should be carefully handled when injecting, especially when used in children or the elderly. Women who are pregnant or breastfeeding should take special precautions, and in some cases, administration should be avoided. This drug should be used according to a doctor's instructions when used in combination with anticancer agents like methotrexate, requiring blood concentration tests to manage therapeutic effects and side effects. Regular blood tests and liver function tests should be conducted to early detect and manage adverse reactions. This drug may cause allergic reactions or injection site pain, fever, and central nervous system symptoms, so if unusual symptoms occur, consult healthcare professionals immediately. Additionally, it may interact with other medications, so it's important to inform if any other drugs are being taken. Elderly patients may have reduced physiological function, requiring more caution during administration. This drug is contraindicated for intrathecal administration, and intravenous injections should be administered slowly while monitoring calcium content. Store out of reach of children and keep it in the original container to maintain quality.

Side effects

  • Anaphylactic reaction
  • urticaria
  • vasculitis
  • transient pain
  • fever
  • paralysis
  • agitation
  • depression
  • diarrhea
  • skin reactions
Show 7 more
  • dry skin
  • stomatitis
  • conjunctivitis
  • mucositis
  • mild hematotoxicity
  • leukopenia
  • vomiting

Not everyone experiences these, and they can vary from person to person.

Storage

This drug should be stored in a sealed container to avoid exposure to air and light. Additionally, it is important to store it in a cool place between 2°C and 8°C to maintain its effectiveness.

Appearance and packaging

Appearance

A transparent yellow injection solution filled in a colorless transparent vial

Package unit

50mg/5mL x 1 vial, 100mg/10mL x 1 vial, 300mg/30mL x 1 vial

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.